The role of social network support on treatment outcomes for medication for opioid use disorder: a systematic review

Navin Kumar[*], Benjamin A. Howell[†], William Oles[‡], Kamila Janmohamed[§],
Selena T. Lee[¶], Patrick G. O'Connor[‖], Marcus Alexander[**]

Abstract

Background. Despite the possible influence of social network support on medication for opioid use disorder (MOUD) treatment, there has been no systematic evaluation of the scientific evidence on the effectiveness of social network support on MOUD.

Methods. We searched electronic research databases, specialist journals and grey literature till February 2020. We included experimental and observational studies regarding individuals receiving MOUD, and intersections with social network support.

Results. Of 4116 articles screened, we identified 41 studies meeting inclusion criteria. Nineteen studies reported treatment retention/adherence as an MOUD outcome. Three were experimental and 16 were observational. Seventeen studies indicated that social network support was related with improved MOUD treatment retention/adherence. Of the studies with statistically significant results, 12 involved family social network support, while five focused on combined family and peer social network support. Twenty-two studies reported reduced drug use/abstinence as an MOUD outcome. Ten were experimental and 12 were observational. Sixteen studies indicated that social network support was related to reduced drug use/abstinence. Of the studies with statistically significant results, 13 involved family social network support, while three focused on either peer network support or combined family and peer network support.

Conclusions. Although evidence was limited, social network support was associated with MOUD treatment outcomes. Interventions around social network support could potentially augment MOUD treatment outcomes. Despite the variety of outcomes and social network support, we suggest the key role of social network support on broad MOUD outcomes.

---

[*]Department of Sociology and Yale Institute for Network Science, Yale University

[†]National Clinician Scholars Program and Section of General Internal Medicine, Yale University School of Medicine and Yale-New Haven Hospital, and VA Connecticut Healthcare System

[‡]Yale Institute for Network Science, Yale University

[§]Yale Institute for Network Science, Yale University

[¶]Yale Institute for Network Science, Yale University

[‖]Section of Internal Medicine, Yale University School of Medicine and Yale-New Haven Hospital

[**]Yale Institute for Network Science, 17 Hillhouse Ave, New Haven, CT 06520; email: marcus.alexander@yale.edu, Human Nature Lab

Introduction

Increasing access to medications for opioid use disorder (MOUD) is a key public health strategy in combating the opioid overdose epidemic [1, 2]. MOUD has several benefits such as decreases in mortality, increases in treatment adherence, decreases in heroin use, and augmented health, social and criminal justice outcomes [3, 4, 5]. World Health Organization (WHO) recommendations indicate that access to MOUD is key to treatment for opioid use disorder [6]. MOUD refers to several medications, primarily opioid agonist medications, like methadone and buprenorphine, and also opioid-antagonist medications such as naltrexone [7]. Although MOUD approaches are the most efficacious evidence-based treatment for opioid use disorder [8], a significant number of MOUD patients do not receive favorable treatment outcomes (e.g. dropping out of treatment programs, illicit drug use) [9, 10]. We need greater understanding of how social network support functions with respect to MOUD treatment outcomes to improve treatment outcomes.

Although clinical delivery characteristics, baseline substance use behaviors, comorbid mental health or substance use disorders and patient demographics influence treatment outcomes [11, 12], less research has focused on how social network support is associated with treatment outcomes. Novel treatment paradigms, such as open access models, have gone a long way in decreasing barriers to treatment and improving engagement, but there is still unexplained variability in patient engagement and therefore an opportunity for improvement [13]. An open-access model is one where prospective patients are quickly enrolled in methadone maintenance treatment, regardless of ability to pay. Patients are provided real-time access to a range of group and individual treatment options [13].

Phenomena as diverse as cooperation, obesity, drug use, smoking, alcohol use may be associated with social networks [14, 15, 16, 17]. Similarly, recent work indicates that social networks, and the social support they provide, here termed social network support, may influence patterns of substance use, help-seeking, and adherence [18, 19, 20]. Previous systematic reviews detailed psychosocial interventions and MOUD [21, 22, 23], and the effectiveness of psychosocial plus any pharmacological interventions versus pharmacological alone for MOUD [24]. However, there is limited research around the role of social network support on MOUD treatment outcomes. Social network support is the social support one receives, positive or negative, from all the people with whom a social relationship is shared [25, 26]. Examples of positive social network support are information that one is cared for and loved or knowledge that one belongs to a social network of communication and mutual obligation [26]. Examples of negative social network support are information that one is not liked or excluded from a social network or group. Social network support in regard to MOUD treatment refers to interventions applying social network support-related techniques (e.g. experimental studies applying family, group therapies or related psychosocial interventions) or interventions that test association between social network support variables and MOUD treatment outcomes (e.g. observational studies with variables such as family or partner support).

The study objective was to review existing scientific evidence on the following research question: For MOUD patients (population), what influence does social network support have on MOUD (intervention) treatment outcomes (outcome)? This systematic review sought to provide policymakers, administrators, practitioners and researchers with a systematic and reproducible strategy to query the literature around the role of social network support on MOUD treatment outcomes. We reviewed evidence under two themes, derived from MOUD outcomes: Treatment

retention/Adherence, Drug use/Abstinence. Within these themes, we divided studies by the following forms of social network support: Family, Peer, Combined family and peer, General.

Methods

We conformed to frameworks and standard tools of the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) [27, 28, 29] and Synthesis without meta-analysis (SWiM) guidelines [30]. The protocol was pre-registered on PROSPERO (CRD42018095645) on May 24, 2018.

Search strategy

We searched online indexes, references in previous reviews/guidelines, and Clinicaltrials.gov. For more details on search strategy see Appendix.

Inclusion/Exclusion criteria

We included studies that met the following criteria:

- randomized controlled trials, quasi-experimental studies and observational studies published in peer-reviewed journals; other scientific publications (e.g. scientific monographs); non-peer reviewed journals and grey literature (technical reports, conference papers).

- participants sought treatment for opioid use or met criteria for opioid abuse, opioid dependence or opioid use disorder.

- one or more variants of MOUD were offered (e.g. methadone, buprenorphine, naltrexone).

- the study reported social network support (e.g. family/partner/friend/peer/neighbor support, social network interventions [25, 26]) as interventions or as predictors for the outcome.

- the study reported adherence to MOUD as an outcome e.g. medication adherence, program retention. There will be no restrictions on study design, population or comparator (if included). Studies excluded from review will be case reports, reviews, systematic literature reviews, qualitative studies, opinion pieces, editorials, comments, news articles, and letters.

Outcomes

Primary outcomes are 1) MOUD retention which refers to time in treatment or length of stay; 2) MOUD adherence which pertains to medication (days the patient took their MOUD etc.); 3) opioid or other illicit drug use (cocaine, methamphetamine etc.), defined as the percentage of urine samples negative for opioids and/or self-reported drug use. For the purposes of the review, we grouped MOUD retention and adherence together, due to their underlying similarity regarding adherence to a MOUD regimen.

Figure 1: Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flow diagram of study selection

Data extraction, review methods, quality assessments and data synthesis

We utilized a standardized template to extract data from each study. More detail on data extraction, review methods, quality assessments and data synthesis is contained in Appendix.

Table 1: Study characteristics related to design of study, MOUD drug used, target population, outcome, number of participants, follow-up and conclusions

Author, date	Place	Study Design	MOUD drug used	Population	Outcomes	Sample characteristics (N, % male, age, ethnicity)	Follow up	Conclusions
Form of social network support: Family								
Anton et al., 1981	USA	Observational retrospective study	Naltrexone	Opioid dependent self-referred patients	Naltrexone maintenance for three months or more	Total N: 65 Naltrexone + HIP N: 40 % male: 85 Mean age: 26.9 Ethnicity: 42.5% White; 57.5% Black Naltrexone + HIP + MFT N: 25 % male: 96 Mean age: 24.8 Ethnicity: 72% White; 28% Black	1 year	Higher retention rate for patients treated with multiple family therapy than those who did not receive multiple family theory.
Carroll et al., 2001	USA	Randomized controlled trial	Naltrexone	Opioid dependent patients who had completed outpatient detoxification	Adherence to naltrexone treatment	N: 127 % male: 76 Mean age: 32 Ethnicity: 77% White	unclear	Patients who attended at least 1 family counselling session had better results for those under the significant other than those in the contingency management group with regards to retention, treatment adherence and drug use outcomes.
Catalano et al., 1997	USA	Randomized controlled trial	Methadone	Opioid dependent parents who had been in methadone treatment for a minimum of 90 days and have one or more children between the ages of 3 and 14 years old living with them at least 50% of the week	Parent self-reported drug-use	N: 35 % male: 25 Mean age: 35.36 Ethnicity: 77% White; 18% Black; Mixed/Other: 5%	3 years	Parents in the experimental group (Standard methadone treatment + supplemental parenting program) had lower levels of opioid use than participants in standard methadone treatment group.
Catalano et al., 1999	USA	Randomized controlled trial	Methadone	Opioid dependent parents who had been in methadone treatment for a minimum of 90 days and have one or more children between the ages of 3 and 14 years old living with them at least 50% of the week	Self-reported frequency of use of marijuana, cocaine, opioids and drug use in previous month	N: 178 % male: 26.7 Mean age: 35.4 Ethnicity: 77% White	3 years	Parents in experimental group who did a parent skills training and home-based case management to reduce parents' risk for relapse had lower levels of opioid use than control participants.
Cerovecki et al., 2013	Croatia	Observational prospective study	Methadone	Opioid dependent patients treated in family medicine settings	Fatal outcome risk factors like quality of relationships and continuation of drug use during previous therapeutic attempts	N: 287 % male: NA Mean age: NA Ethnicity: NA	12 years	Increased fatal outcome for patients with more unstable relationships (where the relationship was marked with frequent arguments or fights) and loss of continuity of care
Davila Torres, 2011	USA	Observational retrospective study	Methadone	Latino opioid dependent patients	Retention and treatment program completion	N: 291 % male: 66.7 Mean age: NA Ethnicity: NA	1 year	Successful treatment completion associated with living in stable housing and higher perceived physician/nurse support.

Table 1: Study Characteristics (continued)

Author, date	Place	Study Design	MOUD drug used	Population	Outcomes	Sample characteristics (N, % male, age, ethnicity)	Follow up	Conclusions
Fals-Stewart and O'Farrell, 2003	USA	Randomized controlled trial	Naltrexone	Opioid dependent individuals living with at least one parent/spouse/intimate partner/family member willing to participate and did not have a current substance use disorder or meet DSM-III-R criteria for schizophrenia, bipolar disorder, or psychosis	Percentage of opioid-free urines	N: 124 % male: 100 Mean age: 32.9 Ethnicity: 66% White; 26% Black; 3% Hispanic; 5% Other	4 years	Male opioid-dependents living with a family member with a family-based naltrexone treatment adherence contract produced better outcomes during treatment.
Fals-Stewart et al., 2001	USA	Randomized controlled trial	Methadone	Opioid dependent male partners who had been married for at least 1 year or in a stable common-law relationship for at least 2 years who had to refrain from seeking additional substance abuse treatment except for self-help meetings like Alcoholics Anonymous	Urine tests	N: 36 % male: 100 Mean age: 38.1 Ethnicity: 18% White; 15% Black; 3% Hispanic	4 years	Patients who received behavioral couples therapy reported greater reductions in drug use severity and family and social problems from baseline to post treatment than patients receiving standard methadone maintenance treatment.
Feng et al., 2018	China	Observational retrospective study	Methadone	Opioid dependent patients enrolled in methadone clinic	Self-reported heroin use or a positive urine morphine test result	N: 2446 % male: 79.2 Mean age: NA Ethnicity: NA	1 year	Higher heroin use concurrent with treatment for patients with family members with history of heroin use.
Gogineni et al., 2001	USA	Observational prospective study	Methadone	Opioid dependent patients enrolled in methadone maintenance treatment clinic	Continued opioid use	N: 252 % male: 56 Mean age: 40.3 Ethnicity: 64% White; 22% Black; 9% Latino/Hispanic; 2% Native American; 3% Other	None	Patients with substance-using live-in partners or drug-using social relationships had higher drug use.
Grey et al., 1986	USA	Observational prospective study	Naltrexone and Methadone	Opioid dependent patients who had been opioid-free for 7 days prior to treatment (for naltrexone) and opioid dependents for at least 1 year for methadone maintenance treatment	Retention (number of required clinic appointments kept)	N: 60 % male: 73.3 Ethnicity: 58.3% White; 11.7% Black; 30.0% Hispanic	3 months	Drug abuse was correlated significantly with perceived family support.

Table 1: Study Characteristics (continued)

Author, date	Place	Study Design	MOUD drug used	Population	Outcomes	Sample characteristics (N, % male, age, ethnicity)	Follow up	Conclusions
Gu et al., 2013	China	Randomized controlled trial	Methadone	Heroin dependent patients recently admitted to the three participating methadone maintenance treatment clinics	Attrition from the methadone maintenance treatment service, which was defined as a failure to visit the methadone maintenance treatment clinic consecutively for at least 1 month immediately prior to the study's completion date	N: 288 % male: 92 Mean age: NA Ethnicity: 98.9% Han	1 year	Patients who received a combination of psycho-social intervention with the standard of-care methadone maintenance treatment service as compared to that of the standard of-care methadone maintenance treatment service alone showed lower likelihood of attrition.
Gu et al., 2014	China	Case-crossover design	Methadone	Opioid dependent patients	Methadone maintenance clinic nonattendance	N: 131 % male: 88 Mean age: NA Ethnicity: NA	1 month	Increased nonattendance at methadone maintenance treatment clinics for patients with interpersonal conflicts with family, financial difficulty and with worry about police arrest.
Heinz et al., 2009	USA	Observational retrospective study	Methadone	Opioid dependent patients with a history of cocaine use	Positive urinalysis tests for cocaine and opioids	N: 635 % male: 54.1 Mean age: 39.2 Ethnicity: 39.5% White; 59% Black; Other: 1.5%	6 years	Reduced cocaine and heroin use for married participants who reported a close relationship with one's partner.
Hikmayan et al., 2012	Indones	Observational prospective study	Methadone	Heroin dependent patients	Retention rate in methadone management treatment clinics	N: 98 % male: NA Mean age: 31.6 Ethnicity: NA	1 year 6 month	Low retention significantly associated with absence of family support.
Hoang et al., 2015	Vietnam	Observational prospective study	Methadone	Opioid dependent patients	Concurrent heroin use after methadone treatment initiation	N: 965 % male: 98.1 Mean age: 34.4 Ethnicity: NA	10 month	Increased continued use of heroin after methadone maintenance treatment with likelihood of family conflict.
Hoang et al., 2018	Vietnam	Observational retrospective study	Methadone	Opioid dependent patients	Concurrent heroin use after methadone treatment initiation	N: 500 % male: 96.8 Mean age: NA Ethnicity: NA	5 years	Increased odds of concurrent heroin use during treatment for patients with no emotional support from family or financial stability.
Hojjat et al., 2017	Iran	Randomized controlled trial	Methadone	Individuals with a substance dependent husband with no history of drug dependence	Relapse rate	Total N: 50 Control % male: NA Mean age: 32.7 Ethnicity: NA Experimental % male: NA Mean age: 30.2 Ethnicity: NA	1 year two month	Harm reduction education in families of patients undergoing methadone maintenance treatment can be effective on their marital satisfaction and treatment retention.

Table 1: Study Characteristics (continued)

Author, date	Place	Study Design	MOUD drug used	Population	Outcomes	Sample characteristics (N, % male, age, ethnicity)	Follow up	Conclusions
Lee et al., 2015	Taiwan	Observational prospective study	Methadone	Heroin dependent patients enrolled in methadone maintenance treatment clinic	Treatment retention	N: 177 % male: 76.9 Mean age: 37.15 Ethnicity: NA	unclear	Increased expressed emotion between family members and patients is linked to retention.
Lin et al., 2011	China	Cross-sectional study	Methadone	Opioid dependent patients enrolled in methadone maintenance treatment clinic	Self-reported drug use and urine tests	N: 560 % male: 84.1 Mean age: 33 Ethnicity: NA	7 months	Perceived family support associated with improved health and negatively correlated with concurrent substance abuse
Lin et al., 2013	Taiwan	Observational prospective study	Methadone	Opioid dependent patients enrolled in methadone maintenance treatment clinic	Retention rate in methadone maintenance treatment clinics	N: 368 % male: 86.4 Mean age: 37.2 Ethnicity: NA	1 year	Perceived higher family support predicted a lower risk of methadone maintenance treatment dropout
Lundgren et al., 2007	USA	Observational prospective study	Methadone	Opioid dependent patients enrolled in methadone maintenance treatment clinic	Longest consecutive stay in methadone maintenance treatment clinic	N: 8258 % male: 65.7 Mean age: 36.5 Ethnicity: 68.6% White; 25.9% Latino; 5.5% Black	6 years	Patients who resided with children, were younger and had no public health insurance were more likely to stay in methadone maintenance treatment for 6 months or less.
Mutasa, 2001	United Kingdom	Observational prospective study	Methadone	Opioid dependent individuals living within catchment area	MST noncompliance (misuse drugs)	N: 45 % male: 66.7 Mean age: NA Ethnicity: 88.89% White; 6.67% South Asian; 4.44% Black	unclear	Medication noncompliance was associated with social company availability, family-related conflicts and peer association.
Nguyen et al., 2017	Vietnam	Observational prospective study	Methadone	Opioid dependent patients enrolled in methadone maintenance treatment clinic	Treatment adherence	N: 241 % male: NA Mean age: NA Ethnicity: NA	4 months	Patients who were reminded by family members by mobile phone to adhere to treatment were more likely to do so.
Roozen et al., 2003	Netherlands	Randomized controlled trial	Naltrexone	Opioid dependent patients	Abstinence for a 6-month treatment period	Naltrexone N: 24 % male: 87 Mean age: 30.5 Ethnicity: NA Methadone N: 20 % male: 82 Mean age: 29.9 Ethnicity: NA	3 years	Patients who received a combination of naltrexone and community reinforced approach had better outcomes than those with traditional treatment.
Shen et al., 2018	China	Observational prospective study	Methadone	Opioid dependent patients enrolled in methadone maintenance treatment clinic	Positive urinalysis tests for heroin use	N: 324 % male: 76.9 Mean age: 45.2 Ethnicity: 83% Han	1 year	Patients with a spouse, child or close family member were less likely to have positive urine tests for heroin.
Tang, 2016	China	Observational prospective study	Methadone	Opioid dependent patients with a history of quitting attempts	Treatment adherence	N: 523 % male: 75.9 Mean age: 38.5 Ethnicity: NA	9 months	Patients are more likely to engage in sexual activity, have stronger family relationships, and experience improved health status post-treatment.
Yandoli et al., 2002	United Kingdom	Randomized controlled trial	Methadone	Patients with at least six months' duration of opioid dependence who agreed to be seen with their partner/family during treatment if required	Frequency of opioid use (allocated as opioid free, occasional users, regular users)	N: 119 % male: 63 Mean age: 28.2 Ethnicity: NA	14 months	Family therapy produced significantly more drug-free participants than standard treatment at six months and at twelve months.
Zhu et al., 2018	USA	Observational retrospective study	Buprenorphine Methadone	Opioid dependent patients	Long-term opioid abstinence (at least 5 years)	N: 699 % male: 65.2 Mean age: 37.4 Ethnicity: NA	3 years	Long-term abstinence was positively associated with greater social support.

Table 1: Study Characteristics (continued)

Author, date	Place	Study Design	MOUD drug used	Population	Outcomes	Sample characteristics (N, % male, age, ethnicity)	Follow up	Conclusions
Form of social network support: Peer								
Monico et al., 2015	USA	Observational prospective study	Buprenorphine	African American opioid dependent patients	Treatment retention and long-term abstinence	N: 300 % male: 60 Mean age: 46.2 Ethnicity: 100% Black	3 and 6 month	12-step meeting during the first 6 months of methadone maintenance treatment associated with superior abstinence outcomes.
Scherbaum et al., 2005	German	Randomized controlled trial	Methadone	Opioid dependent patients	Drug use	N: 73 % male: 73 Mean age: 30 Ethnicity: NA	2 1/2 years	A reduction in drug use was observed in the intervention (psychotherapy) group but this was only observed at the 6-month follow up but not by the end of the study.
Form of social network support: Combined family and peer								
Day et al., 2013	United Kingdom	Cross-sectional analysis	Buprenorphine Methadone	Opioid dependents	Heroin use in the previous month	N: 118 % male: 79 Mean age: 35.5 Ethnicity: 73% White; 14% South Asian; 4% Black, 8% Mixed	6 month	Substance use involvement of heroin using social network was higher amongst patients who had used heroin in the past month.
Day et al., 2018	United Kingdom	Randomized controlled trial	Methadone	Opioid dependent individuals who had been prescribed methadone or buprenorphine for the past 12 months and had reported heroin use on one or more days 28 days prior to beginning of the study	Number of days of heroin use in the past month	N: 83 % male: 79 Mean age: 35.5 Ethnicity: 73% White; 14% South Asian; 4% Black; 8% Mixed	1 year	No significant differences were found between the 3 intervention arms in primary or secondary outcome measures: treatment as usual (TAU, Brief Social Behavior and Network Therapy (BSBNT) ± TAU or Personal Goal Setting (PGS) ± TAU)
Kidorf, 2018	Unclear	Randomized controlled trial and Single group design	Methadone	Opioid dependent individuals recruited from a community syringe exchange or from a methadone maintenance program	Rate of alcohol and other drug use	N: 18 % male: NA Mean age: NA Ethnicity: NA	unclear	Patients with drug-free community support benefited from it clinically.
Rothenberg et al., 2002	US	Prospective study	Naltrexone	Opioid dependent individuals with a significant other who could commit to participating in treatment	Retention in treatment	N: 82 % male: 77 Mean age: 33.6 Ethnicity: 64% White; 25% Hispanic; 11% Black	unclear	Poorer outcomes for patients who used methadone regularly at baseline than heroin only.
Sarasvita et al., 2012	Indones	Observational prospective study	Methadone	Opioid dependent patients enrolled in methadone maintenance treatment clinic	Duration of treatment in days	N: 178 % male: 90 Mean age: 27.2 Ethnicity: 32.6% Javanese; 16.3% Sudanese; 4.5% Bataknese	1 year 6 month	Patients with family support and with less peer support were less likely to drop out.
Torrens et al., 1996	Spain	Observational prospective study	Methadone	Opioid dependent patients	Retention rate	N: 370 % male: 66 Mean age: 29.6 Ethnicity: NA	2 years 10 month	Patients living with family or stable partners had higher rates of retention.

Table 1: Study Characteristics (continued)

Author, date	Place	Study Design	MOUD drug used	Population	Outcomes	Sample characteristics (N, % male, age, ethnicity)	Follow up	Conclusions
Tran et al., 2018	Vietnam	Observational prospective study	Methadone	Opioid dependent patients enrolled in methadone maintenance treatment clinic	Self-reported medication adherence	N: 510 % male: 98.4 Mean age: 36.6 Ethnicity: NA	5 months	Low rate of methadone maintenance treatment non-adherence associated with job stability, engagement in self-care, and active participation of partners, family and friends in the treatment process.
Yang et al., 2013	China	Observational retrospective study	Methadone	Opioid dependent patients enrolled in methadone maintenance treatment clinic	Retention rate in methadone maintenance treatment clinic	N: 2728 % male: 72.8 Mean age: 36.4 Ethnicity: NA	4 years 9 months	Protective factors for methadone maintenance treatment retention were: strong relationships with family, living on support of family or friends and not communicating with former drug taking peers in the past month.
Form of social network support: General								
Smith, 2002	USA	Observational prospective study	Methadone	Male veteran literate opioid dependents individuals	Retention as measured by length of time in treatment	N: 80 % male: 60 Ethnicity: 60% Black; 38.8% White; 1.2% Latino	12 weeks	Length of time in treatment was not predicted by social support, but interaction of perceived social support and orientation towards social support predict therapeutic alliance (adherence).
Wasserman et al., 2001	USA	Observational prospective study	Methadone	Opioid dependent patients with at least 1 month enrollment in methadone or levo-alpha-acetyl-methadol maintenance	Biochemically confirmed opioid and cocaine abstinence	N: 128 % male: 55 Mean age: 45 Ethnicity: 50% White	unclear	Having social networks with less drug users (abstinence specific structural support) correlated with reduced drug use and demoralization for cocaine abstinence but not opioid abstinence. There was no effect for general support.

Note: *Randomized controlled trial (RCT)* refers to a study design that randomly assigns participants to intervention or control groups. *Methadone maintenance treatment (MMT)* refers to the daily use of methadone to reduce opioid cravings and withdrawal symptoms. *Multiple family therapy (MFT)* refers to a combination of multi-generational, structural and general supportive approaches to therapy for patients and their families. *Behavioral couples therapy* (BCT) refers to intensive therapy treatment involving once-weekly couples therapy, individual counseling and methadone for substance-abusing participants. *Community reinforcement approach (CRA)* refers to a combination of psychoeducation, pharmacotherapy, compliance therapy, relation therapy and job counselling.

Results

Included studies

Results from the study selection process are indicated in Figure 1 and general study characteristics displayed in Table 1. Systematic searches yielded 4116 papers imported for screening, with 4087 studies screened for review (29 duplicates, see Figure 1). Screening yielded 213 articles for full-text review by two independent reviewers. Forty-one studies were deemed relevant to the review, summarized in Table 1. Thirteen were experimental studies, 28 were observational studies. The USA (18) and China (seven) were the most represented nations. Treatment and comparison groups were all drawn from opioid-dependent populations. Thirty interventions involved maintenance on methadone, six involved naltrexone, four involved methadone or buprenorphine, one involved methadone or LAAM (levo-alpha-acetyl-methadol), one involved naltrexone and methadone combination therapy, and one involved just buprenorphine.

Figure 2: Evidence for observational studies regarding the role of social network support on treatment outcomes for medication for opioid use disorder. A **supermatrix** covering all study outcome categories (columns) and forms of social network support (rows) by change in the outcome of interest. Each study is represented by a stacked bar. The height of each component corresponds to a quality score representing the suitability of study design with respect to five quality measures: description of inclusion/exclusion criteria, clear presentation of main results, explanation of methodology, presence of descriptive data and definition of variables. Each bar is annotated with the sample size.

Figure 3: Evidence for experimental studies regarding the role of social network support on treatment outcomes for medication for opioid use disorder. A **supermatrix** covering all study outcome categories (columns) and forms of social network support (rows) by change in the outcome of interest. Each study is represented by a stacked bar. The height of each component corresponds to a quality score representing the suitability of study design with respect to five quality measures: allocation concealment, addressing of incomplete outcome data, intent-to-treat analysis, addressing of selection bias and adequate sequence generation. Each bar is annotated with the sample size.

Quality assessments

Tables 2 and 3 indicate the quality of experimental and observational studies. For experimental studies, allocation concealment was rarely reported and its impact on bias was not clear. The quality ratings for observational studies were overall high. We indicated relevant evidence and statistical significance for observational (see Fig 2) and experimental studies (see Fig 3) across treatment retention/adherence and drug use/abstinence outcomes, for each variety of social network support with a harvest plot [31]. Twenty-three observational studies met all five criteria [32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54] Four observational studies met four criteria [55, 56, 57, 58]. Observational studies on treatment retention/adherence, compared to drug use/abstinence, were more likely to fulfil the criteria for quality of execution, with 14 treatment retention/adherence studies meeting all five criteria [42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54]. No experimental studies met all five criteria. Two experimental studies met four criteria, both of which addressed drug use/abstinence [59, 60]. The remaining studies in this review met between zero and three criteria.

Table 2: Quality of Experimental Studies

Study	Sequence generation adequate	Allocation concealment	Baseline data/ selection bias	Incomplete outcome data adequately addressed	Intent-to-treat analysis	Other limitations discussed by authors
Carroll et al., 2001	Yes: urn randomization program	Unclear	Yes: groups differed significantly on baseline intensity of opioid use	Unclear: high attrition after detoxification	Yes	Retrospective study. Not randomized.
Catalano et al., 1997	Yes: block randomization	Unclear	Groups comparable	No: missing data mentioned, but method of addressing omitted	Yes	Results produced at post-test only show immediate effects after intervention, not overall efficacy. Bias from sole examination of parent differences post-test. Does not study molecular processes of family change that produce observed findings.
Catalano et al., 1999	Yes: block randomization	Unclear	Groups comparable	Unclear	Unclear	Retrospective study. Follow-up data unavailable.
Day et al., 2018	Yes: independent randomization algorithm	None: Open trial	Groups comparable	Yes: high attrition in experimental group addressed with high recruitment in experimental group	Yes	Organizational barriers. Discontinuity in staff delivering treatment. Inadequate recruitment for outcome measurement.
Fals-Stewart and O'Farrell, 2003	Unclear	Unclear	Groups comparable	Yes: multiple imputation	No	Naltrexone pharmacotherapy intervention not fully standardized or manually driven. Complacence measured by self-reports. Key secondary outcomes (family relationship function and HIV-risk) behaviors not measured. Poor generalizability due to study sample characteristics and low rate of study participation.
Fals-Stewart et al., 2001	Unclear	Unclear	Groups comparable	No: 5 participants who did not complete treatment were excluded	No	Small sample size. Recall bias from strategy used for scheduling interviews with patients. Underreporting due to stigma and impact of opioid dependence. Bias from retrospective data collection, lack of blinding and the use of proxy informants.
Gu et al., 2013	Yes: block randomization	Adequate Central allocation	Groups comparable	Unclear: attrition from methadone maintenance treatment service was primary outcome	No	Small sample size. Sample overrepresented males. Assessment of family interaction processes limited by self-reporting measures.
Hojjat et al., 2017	Yes: computerized random numbers	Unclear	Groups comparable	Unclear: no missing data reported	No	Patients in cohort experiments other interventions not captured by study.
Kidorf, 2018	Unclear	Unclear	Groups comparable	Unclear	No	Not indicated
Roozen et al., 2003	No randomization	None: No randomization	Groups comparable	Unclear	No	Not indicated

Table 2: Quality of Experimental Studies (continued)

Study	Sequence generation adequate	Allocation concealment	Baseline data/ selection bias	Incomplete outcome data adequately addressed	Intent-to-treat analysis	Other limitations discussed by authors
Rothenberg et al., 2002	No randomization	None: No randomization	No randomization, selection bias possible	No: participants who failed to complete treatment were removed from the trial	No	Inadequate accounting for potential change in family and peer relations as a result of treatment participation.
Scherbaum et al., 2005	Yes: simple randomization via coin flip	Unclear	Groups comparable	Yes: missing data addressed by following the last observation carried forward principle	Yes	Recall bias from a longer recall period during non-attendance episode. Reporting bias from self-reporting. Underreporting of attendance and non-attendance episodes due to inclusion of only the most recent pair, and exclusion of non-attendance duration. Poor generalizability due to study location limitations.
Yandoli et al., 2002	Unclear	Adequate: Central allocation	Groups comparable	Follow-up groups not comparable: high attrition at second follow up leading to differences between treatment groups.	Yes	Temporal ambiguity due to cross-sectional design. Recall bias and social desirability bias due to self-reporting. Underreporting of heroin use as the urine morphine test could only detect use in the past seven days rather than the 30 day period of self-reporting. Poor generalizability as drug-using patterns and economic situations differ across other provinces.

Note: *Sequence generation* refers to the method of generating the allocation sequence (e.g., computer-generated random numbers), and list of any factors for stratification. Examples of adequate sequence generation: random number table; computerized random number generator. *Allocation concealment* denotes the mechanism of implementing the allocation sequence, describing any steps to conceal the sequence until interventions are assigned. Example of adequate allocation concealment: treatment assignments enclosed in opaque sequentially numbered, sealed envelope. *Selection bias* occurs when recruiters selectively enroll patients into the trial based on what the next treatment allocation is likely to be. Example of selection bias addressed: blinding of recruiters; simple randomization. *Incomplete outcome data addressing* refers to issues such as systematic differences in attrition between groups, and overall loss to follow up. These can be addressed by techniques such as the data analyzed in accordance with a pre-specified plan finalized before unblinded outcome data was available. *Intent-to-treat analysis* is adequate when all eligible patients that were randomized are included in analysis. *Methadone maintenance treatment (MMT)* refers to the daily use of methadone to reduce opioid cravings and withdrawal symptoms.

Table 3: Quality of Observational Studies

Study	Methodology explained	Inclusion/ exclusion criteria described	Variables defined	Subjects Ns and descritive data at each stage reported	Main results clearly presented	Limitations / bias discussed by authors
Anton et al., 1981	Yes	Yes	Yes	Yes	Yes	Not a randomized study due to unavailability or unwillingness of patients to participate. Poor generalizability due to small proportion of addicts with families willing to participate in therapy sessions.
Cerovecki et al., 2013	Yes	Yes	Yes	Yes	Yes	Sample size of deceased group too small to determine association between mortality risk and other factors. Recall bias from interview scheduling. Underreporting due to the stigma of opioid dependence. Bias from retrospective data collection, lack of blinding and the use of proxy informants.
Davila Torres, 2011	Yes	Yes	Yes	Yes	Yes	Poor generalizability due to old age of study sample.
Day et al., 2013	Yes	Yes	Yes	Yes	Yes	Cross-sectional study design obscures causal inferences between network support factors and continuing drug use. Poor generalizability due to the exclusion of social support, environment and developmental upbringing.
Feng et al., 2018	Yes	Yes	Yes	Yes	Yes	Baseline limited to making causal inferences due to Randomized controlled trial source. Bias from self-reporting. Weak measure of family members' support on methadone maintenance treatment from a single-item question.
Gogineni et al., 2001	Yes	Yes	Yes	Yes	Yes	Not randomized. Results not confirmed by toxicology Cross-sectional study design obscures causal inference between continued injection and social relationships. Measured of important constructs based on single survey questions with limited response formats.
Grey et al., 1986	Yes	Yes	Yes	Yes	Yes	Small sample size without cross-validation.
Gu et al., 2014	Yes	Yes	Yes	Yes	Yes	Reporting bias from self-reporting. Failure to study all episodes of attendance and non-attendance. Inadequate recording of non-attendance period. Limited generalizability because participants were recruited from two methadone maintenance treatment clinics from one city.
Heinz et al., 2009	Yes	Yes	Yes	No	Yes	Reliance on one dichotomous measure as a proxy for relationship closeness. Lack of information on partner substance use. High selective attrition leading to more unhappily married individuals dropping out of treatment. Insufficient sample of married individuals for outcome comparison. Bias in lack of differentiation between single participants without a significant other and with a significant other but without a close and personal relationship.
Hikmayani et al., 2012	Yes	No	No	No	Yes	Poor generalizability due to potential selection bias. Research instruments explain structure of participant networks but the origins of social support.
Hoang et al., 2015	Yes	Yes	Yes	Yes	Yes	Poor generalizability due to selection bias in sample for wealthier, more motivated individuals with more stable families. Sample disproportionately male. Bias from loss to follow-up.
Hoang et al., 2018	Yes	Yes	Yes	Yes	Yes	Unverified information obtained from methadone maintenance treatment clinical records. Overestimation of concurrent heroin use due to high level of missing data. Biased from loss of patients to follow-up. Missing data limit analysis on association between psychiatric comorbidities and concurrent heroin use.
Lee et al., 2015	Yes	Yes	Yes	Yes	Yes	Temporal ambiguity from cross-sectional study design. Recall bias and social-desirability due to self-reporting. Inconsistency in drug use assessment tools affected verification of status. Self-reporting for the past 30 days and urine test (limited to past 7 days) gave inconsistent assessments. Poor generalizability because of specific geographic focus of study.

Table 3: Quality of Observational Studies (continued)

Study	Methodology explained	Inclusion/ exclusion criteria described	Variables defined	Subjects Ns and de- scritive data at each stage reported	Main results clearly pre- sented	Limitations / bias discussed by authors
Lin et al., 2011	Yes	Yes	Yes	Yes	Yes	Cross-sectional study design limited causal inferences. Poor generalizability due to modesty of drug use in study sites.
Lin et al., 2013	Yes	Yes	Yes	No	Yes	Poor generalizability due to specificity of study group.
Lundgren et al., 2007	Yes	Yes	Yes	Yes	Yes	Poor generalizability due to expansive insurance coverage and treatment programs of study location.
Monico et al., 2015	Yes	Yes	Yes	Yes	Yes	Poor generalizability due to over-representation of African Americans with access to BMT clinics.
Mutasa, 2001	Yes	Yes	No	Yes	Yes	Statistical short-fall due to small sample numbers.
Nguyen et al., 2017	Yes	Yes	Yes	Yes	Yes	Recall bias due to self-reporting. Poor generalizability as sampling method was limited to mountainous settings. Cross-sectional design obscured causal relations between methadone maintenance treatment adherence and determinants.
Sarasvita et al., 2012	Yes	Yes	Yes	Yes	Yes	Invalid predictors of retention for longer studies due to six-month observation period.
Shen et al., 2018	Yes	Yes	Yes	Yes	Yes	Cross-sectional study design hinders causal inference. Social desirability and recall biases due to self-reporting. Underestimation of heroin use prevalence due to the 7-day detection limit of urine tests. Unrobust measure of social network functionality function due to assessment form a single question. Poor generalizability of the study due to location.
Smith, 2002	Yes	Yes	Yes	Yes	Yes	Poor generalizability due to homogeneity of sample (same gender and shared military history). Fully male sample. Limited follow-up interviews due to compromised power to detect significant findings.
Tang, 2016	Yes	Yes	Yes	Yes	Yes	Social desirability bias through under-reporting drug use and availability of comprehensive psychological counseling to methadone maintenance treatment clients Poor generalizability due to study location.
Torrens et al., 1996	Yes	Yes	Yes	Yes	Yes	Retention rate in Spain influenced by long-term methadone policy. Poor generalizability of study to countries with greater experience with methadone maintenance.
Tran et al., 2018	Yes	Yes	Yes	No	Yes	Cross-sectional design obscured causal associations between adherence and its determinants. Recall bias from self-reporting. Sample size too small due to convenience sampling. Poor accuracy of medication adherence measurement due to self-reporting.
Wasserman et al., 2001	Yes	Yes	Yes	Yes	Yes	Short follow-up period limited detection of independent effects. Single instrument used to measure social support. Undercounting of social network participants due to restriction to household members only. Study cannot make causal inferences about social support and abstinence.
Yang et al., 2013	Yes	Yes	Yes	Yes	Yes	Poor generalizability due to limited geographic location of study participants.
Zhu et al., 2018	Yes	Yes	Yes	Yes	Yes	Recall bias due to self-reporting opioid use. Potential correlates associated with opioid abstinence not measured. Statistical significance of difference between abstinent and non-abstinent groups needs to be further ascertained

Note: *Methodology explained* refers to the methodology being clearly explained in the study. *Inclusion/exclusion criteria* described denotes studies that clearly explain the inclusion and exclusion criteria for participants enrolled in the intervention. *Variables defined* means that all variables for analysis are clearly defined. *Number of individuals at each state reported/descriptive data* refers to studies that indicate N of participants at each state e.g. recruitment, treatment etc. *Main results clearly presented* denotes studies denotes studies where outcome data is clearly illustrated. *Methadone maintenance treatment (MMT)* refers to the daily use of methadone to reduce opioid cravings and withdrawal symptoms.

Social network support category assignment

We assigned studies one of the following social network support categories: family, peer, combined family and peer, general. Family social network support connoted studies where family members such as partner, parents or siblings provided support to the patient. Peer social network support denoted studies where peers such as friends, colleagues or other patients provided support. Studies involving outpatient group therapy or community-based support groups (Narcotics Anonymous, Alcoholics Anonymous) were considered peer social network support. Combined family and peer social network support included aspects of both family and peer social network support. General social network support involved social network support that was not related to family, peer, combined family and peer, or general social network support e.g. some studies indicated unspecified social network support.

Treatment retention/adherence

Nineteen studies reported treatment retention/adherence as an MOUD outcome. Three were experimental [61, 62, 63] and 16 were observational [43, 57, 44, 48, 53, 45, 51, 42, 49, 64, 46, 52, 58, 50, 47, 54]. Seventeen studies indicated that social network support was related with improved MOUD treatment retention/adherence [43, 57, 44, 48, 62, 63, 53, 45, 51, 42, 49, 64, 46, 52, 58, 50, 47]. There was one RCT which improved treatment retention/adherence [62]. Most statistically significant results involved family social network support, with a few studies focused on combined family and peer social network support. There was a single study on general social network support with statistically significant results and no studies on peer social network support that demonstrated statistically significant results.

Family social network support

Eleven of 13 studies exploring family social network support within the treatment retention/adherence outcome demonstrated significant improvements in treatment retention/adherence [62, 53, 52, 58, 50, 48, 64, 46, 49, 45, 51] and two had no significant change [61, 47]. Improvements in treatment outcome were found in both experimental [62, 45] and observational studies [53, 52, 58, 50, 48, 64, 46, 49, 51]. In one of the experimental studies, differences between control and treatment groups were large [62]. The study reported lower estimated probability of attrition at Month 12 [0.35 (control) vs. 0.55 (treatment)], higher median number of days of attendance [Month 6: 147 vs. 91 days; end-date: 225 vs. 142 days] [62]. The researchers evaluated the relative efficacy of a combination of a psychosocial intervention and standard of care MOUD versus standard of care on methadone attrition and treatment attendance. Family members provided support (e.g. recognizing participant improvement in daily life after starting MOUD) during the family-centric sessions of the interventions. In the other experimental study [45], some participants received multiple family therapy and the standard therapy, with the rest receiving the standard therapy which included counseling, psychotherapy and outreach. Multiple family therapy sought to build and strengthen family ties, support parents and partners in monitoring patient behavior, among other goals. Findings indicated that the multiple family therapy group had a larger continuous time of naltrexone ingestion and remained in the treatment program longer than clients who did not receive multiple family therapy [45]. For the observational studies, living with one's children,

good family relationships and higher levels of perceived family support were associated with improved MOUD outcomes [51, 53, 52]. Conversely, absence of family support and living in an unstable relationship (where the relationship was marked with frequent arguments or fights) were related to reduced MOUD outcomes [46, 64].

Combined family and peer social network support

All five studies exploring combined family and peer social network support within the treatment retention/adherence outcome indicated statistically significant outcomes [43, 57, 44, 63, 42]. Improvements in treatment outcome were found in one experimental study [63] and four observational studies [43, 57, 44, 42]. The experimental study, applying behavioral naltrexone therapy, reported a positive correlation between length of time in treatment, and adherence and opioid-free urine samples [63]. Behavioral Naltrexone Therapy was delivered over a six-month period in weekly and network therapy sessions, comprised of Relapse Prevention, Community Reinforcement Approach and Network Therapy. For the observational studies, positive family relationships, no communication with former drug-taking peers and disclosing one's health issues to friends were associated with retention [44, 57].

General social network support

We found one study that explored general social network support [54]. The results were statistically non-significant.

Drug use/abstinence

Twenty-two studies reported drug use/abstinence as an MOUD outcome. Ten were experimental [65, 66, 67, 68, 69, 70, 71, 59, 60, 72] and 12 were observational [34, 33, 55, 35, 36, 37, 56, 38, 39, 40, 41, 32]. Sixteen studies indicated that social network support was related with reduced drug use/abstinence [67, 68, 69, 33, 55, 35, 36, 72, 37, 41, 56, 70, 59, 38, 71, 39]. Several RCTs demonstrated the role of social network support in decreasing drug use/abstinence [67, 68, 69, 70, 59, 71]. The most commonly detailed variant was family social network support, while six studies explored combined family and peer social network support, peer social network support, or general social network support.

Family social network support

Thirteen of 16 studies exploring family social network support within the drug use/abstinence outcome demonstrated significant improvements in treatment retention/adherence [67, 68, 69, 33, 55, 35, 36, 37, 56, 70, 38, 71, 39] and three had no significant change [34, 65, 66]. Improvements in outcome were indicated in five experimental studies [67, 68, 69, 70, 71] and eight observational studies [33, 55, 35, 36, 37, 56, 38, 39]. Two of the experimental studies reported large differences between control and treatment groups. The first study [71] reported a higher proportion of drug-free patients six and twelve months in both intervention groups (22% and 15% for family therapy) compared to the standard treatment group (5% and 0%) and low contact group (8% at both marks). The researchers evaluated the efficacy of family therapy compared to a "low contact"

intervention and standard psychotherapy. All groups also received MOUD. The family intervention comprised of up to sixteen sessions and involved the patient's family or partner. Sessions were based on the discussion of family relationships and MOUD. The low contact treatment comprised of monthly, standardized 30-minute interviews for up to 12 months. Standard treatment involved supportive counselling and the delivery of information related to managing drug use. In the other experimental study repoting large differences between control and treatment groups [67], patients were assigned to a supplemented MOUD treatment with 33 sessions of family training and nine months of home-based case management, or the control group with standard MOUD. Family training focused on relapse prevention and coping, anger management and child development. At 12 months, participants in the treatment arm reported less drug use than those in the control arm [67]. For the observational studies, increased social support [39] and having a spouse or child in one's social network [38, 55] were associated with reduced drug use and abstinence. Conversely, factors such as family conflict [56], interactions with drug-using friends [56, 33] and low family support [58] were associated with poorer treatment outcomes.

Peer social network support

There were two studies, both with statistically significant outcomes, which explored peer social network support within the drug use/abstinence outcome [41, 59]. In the experimental study based in Germany, participants were assigned to MOUD or MOUD and group psychotherapy. Patients in the psychotherapy group demonstrated less drug use than control participants [59]. Psychotherapy centered on the patient's understanding of situations predisposing drug use. In the observational study, narcotics anonymous meeting attendance in the past six months was associated with drug abstinence [41].

Combined family and peer social network support

We found one study that explored combined family and peer social network support within the drug-use/abstinence outcome that had statistically significant results [19]. The remaining two studies did not demonstrate significant results [60, 32]. In the experimental study demonstrating statistically significant results [19], individuals who inject drugs were recruited from a community needle exchange group and an MOUD program. Patients attended a weekly community support group with a drug-free family or friend, and participated in weekly community activities to expand drug-free social support. Results indicated reductions in heroin use (27 vs. 17 days/month), intravenous drug use (27 days vs. 20 days/month) and number of injections (123 vs. 48 injections/month).

General social network support

A single study explored general social network support within the drug use/abstinence outcome [40]. Results were non-significant.

Synthesis

Table 4 synthesized the 41 studies per theme and outcome indicating positive treatment effects or no effect. Table 4 also indicated whether biases may have understated or over-reported treatment

effects, if any. Evidence was not consistent for either outcome, although studies overall indicated that social network support was positively associated with MOUD treatment outcomes. This information was derived from Table 2. For experimental studies, bias was considered likely to understate positive outcomes in one study, to exaggerate in four and unclear in the remaining eight studies. The most common source of bias for experimental studies was the lack of intent-to-treat analysis.

Table 4: Synthesis

Significance of outcome	Study	Form of social network support	MOUD drug used	Intervention (if any)	Possible impact of bias on treatment effect, if any (understate, exaggerate, no effect, unclear)
Outcome: Treatment Retention/Adherence					
Positive outcome at P < 0.05	Anton et al., 1981	Family	Naltrexone		
	Cerovecki et al., 2013	Family	Methadone		
	Davila Torres, 2011	Family	Methadone		
	Grey et al., 1986	Family	Naltrexone and Methadone		
	Gu et al., 2013	Family	Methadone	Individual + Family-based counseling	Exaggerate
	Gu et al., 2014	Family	Methadone		
	Hikmayani et al., 2012	Family	Methadone		
	Lee et al., 2015	Family	Methadone		
	Lin et al., 2013	Family	Methadone		
	Lundgren et al., 2007	Family	Methadone		
	Nguyen et al., 2017	Family	Methadone		
	Rothenberg et al., 2002	Combined family and peer	Naltrexone	Behavioral naltrexone therapy	Unclear
	Sarasvita et al., 2012	Combined family and peer	Methadone		
	Tang, 2016	Family	Methadone		
	Torrens et al., 1996	Combined family and peer	Methadone		
	Tran et al., 2018	Combined family and peer	Methadone		
	Yang et al., 2013	Combined family and peer	Methadone		
No effect	Carroll et al., 2000	Family	Naltrexone	Standard naltrexone treatment vs. Naltrexone treatment + CM vs. Naltrexone treatment + CM + Significant other involvement	Unclear
	Smith, 2002	General	Methadone		
Outcome: Drug use/Abstinence					
Positive outcome at P < 0.05	Catalano et al., 1999	Family	Methadone	Focus on families	Unclear
	Fals-Stewart et al., 2001	Family	Methadone	Individual counseling + Methadone treatment vs. Couples therapy + Individual counseling + Methadone treatment	Exaggerate
	Fals-Stewart, O'Farrell, 2003	Family	Naltrexone	Behavioral family counseling + Individual naltrexone treatment vs Individual-based naltrexone treatment	Unclear
	Feng et al., 2018	Family	Methadone		
	Heinz et al., 2009	Family	Methadone		
	Hoang et al., 2015	Family	Methadone		
	Hoang et al., 2018	Family	Methadone		

Table 4: Synthsis (continued)

Significance of outcome	Study	Form of social network support	MOUD drug used	Intervention (if any)	Possible impact of bias on treatment effect, if any (understate, exaggerate, no effect, unclear)
	Kidorf, 2018	Combined family and peer	Methadone		Unclear
	Lin et al., 2011	Family	Methadone		
	Monico et al., 2015	Peer	Buprenorphine		
	Mutasa, 2001	Family	Methadone		
	Scherbaum et al., 2005	Peer	Methadone	Methadone treatment vs. Psychotherapy + Methadone treatment	Exaggerate
	Shen et al., 2018	Family	Methadone		Unclear
	Roozen et al., 2003	Family	Naltrexone	Community reinforcement approach + Naltrexone therapy	Unclear
	Yandoli et al., 2002	Family	Methadone	Family therapy + SCT vs "Low contact" + SCT vs Standard clinic treatment (SCT)	Exaggerate
	Zhu et al., 2018	Family	Buprenorphine, Methadone	Methadone treatment vs. Buprenorphine/Naloxone	Exaggerate
No effect	Catalano et al., 1997	Family	Methadone	Standard methadone treatment vs. Standard methadone treatment + Supplemental parenting program	Unclear
	Day et al., 2013	Combined family and peer	Buprenorphine, Methadone	Network drug use + General support	Unclear
	Day et al., 2018	Combined family and peer	Methadone	Treatment as usual vs. Social behavior and network therapy	Understate
	Gogineni et al., 2000	Family	Methadone		
	Hojjat et al., 2016	Family	Methadone	Group family training + Methadone therapy vs. Methadone therapy	Unclear
	Wasserman et al., 2000	General	Methadone		

Discussion

In this systematic review, we presented a current and comprehensive synthesis of the published literature on the role of social network support on MOUD treatment outcomes. We examined the effect of social network support on two MOUD treatment outcomes: Treatment retention/adherence; Drug use/abstinence. We detailed 41 observational and experimental studies over a range of social network support variants. Overall, social network support was associated with improved MOUD treatment outcomes. However, given the large proportion (21%) of non-significant findings [60, 34, 65, 40, 66, 32, 61, 54], more research is necessary to establish the relationship between social network support and MOUD treatment outcomes. We were unable to conduct a meta-analysis due to variations within outcomes. Future studies can explore if certain variants of social network support are more effective than others at improving MOUD treatment retention/adherence. Quality of observational studies was overall high, but quality of experimental studies was lower. Previous reviews explored psychosocial interventions and MOUD [21, 22, 23], but there is limited work around the effect of social network support on MOUD outcomes. We thus extend the literature by detailing the role of social network support on MOUD outcomes, broadening the scope of social networks regarding health outcomes. Given the several promising studies in our review, utilizing social network support in MOUD treatment may improve overall treatment outcomes.

Our results did not indicate whether some variants of social network support were more effective than others in improving treatment outcomes. The evidence base for family social network support appears the largest, compared to other variants. Thus, treatment providers wishing to add a social network support component to their interventions may use family social network support given the overall limited evidence. Family social network support is associated with improved treatment outcomes [37], especially in jurisdictions such as China, where families are often a large part of a patient's life [37]. We suggest that interventions harnessing family social network support could be more efficacious in societies where families are heavily involved in a patient's life. Future research can explore how to leverage on socio-cultural norms to improve treatment outcomes.

Findings did not detail if combined family and peer social network support was more effective at improving treatment outcomes, compared to interventions focused on peer or family social network support. Our results indicated that family or peer social network support on their own may contribute to improved treatment outcomes, so it may be that these combined would also have a similar or improved effect on treatment outcomes. Future work can explore if interventions that combine different variants of social network support are more effective than interventions that use a single variant of social network support. If combined social network support interventions are found to be more efficacious, such approaches can be used to augment existing large-scale MOUD programs.

While social network support seems to have an overall positive influence on MOUD treatment outcomes, some forms of peer and family interaction may have negative effects on treatment outcomes. Family member opioid prescription [73] and peer opioid misuse may reduce patent treatment outcomes [74]. This may suggest that social network support interventions which involve family and/or peers may be more effective if the patient's social network has minimal numbers of opioid users. It is likely not possible to prevent patients from interacting with friends or families who use opioids, prescribed or otherwise. Treatment providers can survey patients to

better understand the opioid use practices in their social network to see if this affects treatment outcomes. Interventions can be customized for patients who have a large number of opioid using contacts. It may also be possible to engage patients with such social networks in disseminating harm reduction-centric information around opioid use to their social network. This may extend the reach of social network support interventions in not only improving patient outcomes, but also improving broader community well-being. Future work can detail how to engage MOUD patients as providers of evidence-based opioid-related messaging.

Our findings are of great relevance given varied MOUD treatment outcomes. With MOUD being the most effective treatment for opioid use disorder, it is critical that researchers develop the most efficacious MOUD intervention. Our results may suggest that social network techniques can be integrated effectively into existing MOUD approaches to improve treatment outcomes. Governments and public health authorities seeking to improve treatment outcomes can incorporate some of the MOUD interventions noted in our review. We thus provide some policy implications. Public health authorities can encourage or provide a financial incentive for treatment providers who wish to use social network support or other similar techniques to augment MOUD. Such agencies could incentivize treatment providers to include different forms of social network support in their programs to determine which is most efficacious and simultaneously build the research base on social network support in MOUD approaches. Similarly, in absence of a large evidence base for social network support-based MOUD approaches, treatment providers with generic approaches (i.e. without any form of behavioral approach) can encourage patients to seek social support from their family, friends or peers.

The main strength of the study is that we applied a reproducible and transparent procedure for a systematic literature review. A strength is the explicit inclusion/exclusion criteria which centered on clearly delineated MOUD outcomes. We detailed the population, intervention and outcomes included, along with data extraction methods and search strategy. We also centered on the specific variants of social network support on MOUD treatment outcomes.

Limitations

Most of the studies had key methodological concerns. We emphasized more robust study designs and assessed the probable impact of bias to compensate for methodological weaknesses. Possible sources of bias were: group baseline differences; selection bias; attrition bias; differential rates of follow-up. Selection bias may have exaggerated or under-reported treatment effects. If rates of attrition were relatively high or greater in untreated groups, there may be a possibility that treatment effects were overestimated if participants lost to follow-up had greater negative outcomes. A few studies in this review conducted analysis to control for bias through multivariate analysis and/or comparison of losses to follow-up with those followed-up. Attempts to account for biases may not always be successful and we thus assessed the risk of biases (see Table 4), providing an assessment of probable impact of bias on various outcomes. Limitations also arose from differences in methods of reviewed studies, making it more complex to assess or synthesize all studies under the same rubric. The details provided on methods and analysis was highly varied, possibly leading to fluctuations in the confidence level of results.

Conclusions

Although evidence was limited, social network support seems related to a range of MOUD treatment outcomes. Interventions around social network support could potentially augment MOUD treatment outcomes, possibly playing a role in mitigating the opioid epidemic. Future research can explore other forms of social network support. For example, the role of employer social network support may be important to treatment outcomes given the role of workplace authority figures in the lives of MOUD patients [75].

References

[1] Murthy Vivek H. Ending the opioid epidemic—a call to action *New England Journal of Medicine.* 2016;375:2413–2415.

[2] Crowley Ryan, Kirschner Neil, Dunn Andrew S, Bornstein Sue S. Health and public policy to facilitate effective prevention and treatment of substance use disorders involving illicit and prescription drugs: An American College of Physicians position paper *Annals of internal medicine.* 2017;166:733–736.

[3] Mattick Richard P, Breen Courtney, Kimber Jo, Davoli Marina. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence *Cochrane database of systematic reviews.* 2009.

[4] Gowing Linda, Farrell Michael, Bornemann Reinhard, Sullivan Lynn E, Ali Robert. Substitution treatment of injecting opioid users for prevention of HIV infection *Cochrane database of systematic reviews.* 2008.

[5] Tilson Hugh, Aramrattana Apinun, Bozzette Samuel, et al. Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence *Washington, DC: Institute of Medicine.* 2007.

[6] World Health Organization, Department of Mental Health and Substance Abuse . WHO | Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence tech. rep.World Health Organization 2009.

[7] Hedrich Dagmar, Alves Paula, Farrell Michael, Stöver Heino, Møller Lars, Mayet Soraya. The effectiveness of opioid maintenance treatment in prison settings: a systematic review *Addiction.* 2012;107:501–517.

[8] Fanucchi Laura, Springer Sandra A, Korthuis P Todd. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV *Current HIV/AIDS Reports.* 2019;16:1–6.

[9] Feelemyer Jonathan, Des Jarlais Don, Arasteh Kamyar, Abdul-Quader Abu S, Hagan Holly. Retention of participants in medication-assisted programs in low-and middle-income countries: an international systematic review *Addiction.* 2014;109:20–32.

[10] Burns Lucy, Gisev Natasa, Larney Sarah, et al. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia *Addiction.* 2015;110:646–655.

[11] Kelly Sharon M, O'Grady Kevin E, Mitchell Shannon Gwin, Brown Barry S, Schwartz Robert P. Predictors of methadone treatment retention from a multi-site study: a survival analysis *Drug and alcohol dependence.* 2011;117:170–175.

[12] Proctor Steven L, Copeland Amy L, Kopak Albert M, Hoffmann Norman G, Herschman Philip L, Polukhina Nadiya. Predictors of patient retention in methadone maintenance treatment. *Psychology of Addictive Behaviors.* 2015;29:906.

[13] Madden Lynn M, Farnum Scott O, Eggert Kathryn F, et al. An investigation of an open-access model for scaling up methadone maintenance treatment *Addiction.* 2018;113:1450–1458.

[14] Christakis Nicholas A, Fowler James H. The collective dynamics of smoking in a large social network *New England journal of medicine.* 2008;358:2249–2258.

[15] Fowler James H, Christakis Nicholas A. Cooperative behavior cascades in human social networks *Proceedings of the National Academy of Sciences.* 2010;107:5334–5338.

[16] Kim David A, Hwong Alison R, Stafford Derek, et al. Social network targeting to maximise population behaviour change: a cluster randomised controlled trial *The Lancet.* 2015;386:145–153.

[17] Shakya Holly B, Stafford Derek, Hughes D Alex, et al. Exploiting social influence to magnify population-level behaviour change in maternal and child health: study protocol for a randomised controlled trial of network targeting algorithms in rural Honduras *BMJ open.* 2017;7:e012996.

[18] Eitan Shoshana, Emery Michael A, Bates ML Shawn, Horrax Christopher. Opioid addiction: Who are your real friends? *Neuroscience & Biobehavioral Reviews.* 2017;83:697–712.

[19] Kidorf Michael, Latkin Carl, Brooner Robert K. Presence of drug-free family and friends in the personal social networks of people receiving treatment for opioid use disorder *Journal of substance abuse treatment.* 2016;70:87–92.

[20] Wagner Karla D, Iverson Ellen, Wong Carolyn F, et al. Personal social network factors associated with overdose prevention training participation *Substance use & misuse.* 2013;48:21–31.

[21] Dugosh Karen, Abraham Amanda, Seymour Brittany, McLoyd Keli, Chalk Mady, Festinger David. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction *Journal of addiction medicine.* 2016;10:91.

[22] Brown Aaron R. A systematic review of psychosocial interventions in treatment of opioid addiction *Journal of Social Work Practice in the Addictions.* 2018;18:249–269.

[23] Dutra Lissa, Stathopoulou Georgia, Basden Shawnee L, Leyro Teresa M, Powers Mark B, Otto Michael W. A meta-analytic review of psychosocial interventions for substance use disorders *American Journal of Psychiatry.* 2008;165:179–187.

[24] Amato Laura, Minozzi Silvia, Davoli Marina, Vecchi Simona. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification *Cochrane Database of Systematic Reviews.* 2011.

[25] Huberman Bernardo A, Romero Daniel M, Wu Fang. Social networks that matter: Twitter under the microscope *arXiv preprint arXiv:0812.1045.* 2008.

[26] Pearson Judith E. The definition and measurement of social support. *Journal of Counseling & Development.* 1986.

[27] Moher David, Shamseer Larissa, Clarke Mike, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement *Systematic reviews.* 2015;4:1.

[28] Liberati Alessandro, Altman Douglas, Tetzlaff Jennifer, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions *Bmj.* 2009;339.

[29] Higgins Julian PT, Green Sally. *Cochrane handbook for systematic reviews of interventions*;4. John Wiley & Sons 2011.

[30] Campbell Mhairi, McKenzie Joanne E, Sowden Amanda, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline *bmj.* 2020;368.

[31] Crowther Mark, Avenell Alison, MacLennan Graeme, Mowatt Graham. A further use for the Harvest plot: a novel method for the presentation of data synthesis *Research Synthesis Methods.* 2011;2:79–83.

[32] Day E., Copello A., Karia M., et al. Social network support for individuals receiving opiate substitution treatment and its association with treatment progress *European Addiction Research.* 2013;19:211–21.

[33] Feng N., Lin C., Hsieh J., Rou K., Li L.. Family Related Factors and Concurrent Heroin Use in Methadone Maintenance Treatment in China *Substance Use & Misuse.* 2018;53:1674–1680.

[34] Gogineni A., Stein M. D., Friedmann P. D.. Social relationships and intravenous drug use among methadone maintenance patients *Drug & Alcohol Dependence.* 2001;64:47–53.

[35] Hoang T. V., Ha T. T., Hoang T. M., et al. Impact of a methadone maintenance therapy pilot in Vietnam and its role in a scaled-up response *Harm Reduction Journal.* 2015;12:39.

[36] Hoang T., Nguyen H., Shiraishi R. W., et al. Factors associated with concurrent heroin use among patients on methadone maintenance treatment in Vietnam: A 24-month retrospective analysis of a nationally representative sample *International Journal of Drug Policy.* 2018;55:113–120.

[37] Lin C., Wu Z., Detels R.. Family support, quality of life and concurrent substance use among methadone maintenance therapy clients in China *Public Health.* 2011;125:269–74.

[38] Shen L., Assanangkornchai S., Liu W., et al. Influence of social network on drug use among clients of methadone maintenance treatment centers in Kunming, China *PLoS ONE [Electronic Resource].* 2018;13:e0200105.

[39] Zhu Y., Evans E. A., Mooney L. J., et al. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial *Journal Of Neuroimmune Pharmacology: The Official Journal Of The Society On NeuroImmune Pharmacology.* 2018;09:09.

[40] Wasserman D. A., Stewart A. L., Delucchi K. L.. Social support and abstinence from opiates and cocaine during opioid maintenance treatment *Drug & Alcohol Dependence.* 2001;65:65–75.

[41] Monico L. B., Gryczynski J., Mitchell S. G., Schwartz R. P., O'Grady K. E., Jaffe J. H.. Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes *Journal of Substance Abuse Treatment.* 2015;57:89–95.

[42] Sarasvita R., Tonkin A., Utomo B., Ali R.. Predictive factors for treatment retention in methadone programs in Indonesia *Journal of Substance Abuse Treatment.* 2012;42:239–46.

[43] Torrens M., Castillo C., Perez-Sola V.. Retention in a low-threshold methadone maintenance program *Drug & Alcohol Dependence.* 1996;41:55–9.

[44] Yang F., Lin P., Li Y., et al. Predictors of retention in community-based methadone maintenance treatment program in Pearl River Delta, China *Harm Reduction Journal.* 2013;10:3.

[45] Anton R. F., Hogan I., Jalali B., Riordan C. E., Kleber H. D.. Multiple family therapy and naltrexone in the treatment of opiate dependence *Drug & Alcohol Dependence.* 1981;8:157–68.

[46] Cerovecki V., Tiljak H., Ozvacic Adzic Z., Krizmaric M., Pregelj P., Kastelic A.. Risk factors for fatal outcome in patients with opioid dependence treated with methadone in a family medicine setting in Croatia *Croatian Medical Journal.* 2013;54:42–8.

[47] Davila Torres Rena R.. Behavioral factors associated with retention of Hispanics in a methadone maintenance outpatient program *Dissertation Abstracts International Section A: Humanities and Social Sciences.* 2011;72:90.

[48] Grey C., Osborn E., Reznikoff M.. Psychosocial factors in outcome in two opiate addiction treatments *Journal of Clinical Psychology.* 1986;42:185–9.

[49] Gu Jing, Xu Huifang, Lau Joseph T. F., et al. Situation-specific factors predicting nonadherence to methadone maintenance treatment: a cross-sectional study using the case-crossover design in Guangzhou, China *AIDS Care.* 2014;26:S107–S112.

[50] Lee C. H., Wang T. J., Tang H. P., Liu Y. H., Bell J.. Familial expressed emotion among heroin addicts in methadone maintenance treatment: does it matter? *Addictive Behaviors.* 2015;45:39–44.

[51] Lundgren L. M., Sullivan L. M., Maina A. W., Schilling R. F.. Client factors associated with length of stay in methadone treatment among heroin users who inject drugs: quantitative analysis of state-level substance abuse treatment utilization data *Journal of Addiction Medicine.* 2007;1:26–32.

[52] Nguyen L. H., Nguyen H. T. T., Nguyen H. L. T., Tran B. X., Latkin C. A.. Adherence to methadone maintenance treatment and associated factors among patients in Vietnamese mountainside areas *Substance Abuse Treatment, Prevention, & Policy.* 2017;12:31.

[53] Tang Songyuan. Factors associated with effectiveness of Methadone Maintenance Treatment in Yunnan province of China *Dissertation Abstracts International: Section B: The Sciences and Engineering.* 2016;76:No Pagination Specified.

[54] Smith Jennifer Loretta. Treatment outcome among methadone recipients: Influence of perceived social support and orientation towards social support *Dissertation Abstracts International: Section B: The Sciences and Engineering.* 2002;63:551.

[55] Heinz A. J., Wu J., Witkiewitz K., Epstein D. H., Preston K. L.. Marriage and relationship closeness as predictors of cocaine and heroin use *Addictive Behaviors.* 2009;34:258–63.

[56] Mutasa H. C.. Risk factors associated with noncompliance with methadone substitution therapy (MST) and relapse among chronic opiate users in an Outer London community *Journal of Advanced Nursing.* 2001;35:97–107.

[57] Tran B. X., Nguyen L. H., Tran T. T., Latkin C. A.. Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients *PLoS ONE [Electronic Resource].* 2018;13:e0190941.

[58] Lin H. C., Chen K. Y., Wang P. W., et al. Predictors for dropping-out from methadone maintenance therapy programs among heroin users in southern Taiwan *Substance Use & Misuse.* 2013;48:181–91.

[59] Scherbaum N., Kluwig J., Specka M., et al. Group psychotherapy for opiate addicts in methadone maintenance treatment - A controlled trial *European Addiction Research.* 2005;11:163–171.

[60] Day E., Copello A., Seddon J. L., et al. A pilot feasibility randomised controlled trial of an adjunct brief social network intervention in opiate substitution treatment services *BMC Psychiatry.* 2018;18:8.

[61] Carroll K. M., Ball S. A., Nich C., et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement *Archives of General Psychiatry.* 2001;58:755–61.

[62] Gu J., Lau J. T., Xu H., et al. A randomized controlled trial to evaluate the relative efficacy of the addition of a psycho-social intervention to standard-of-care services in reducing attrition and improving attendance among first-time users of methadone maintenance treatment in China *AIDS & Behavior.* 2013;17:2002–10.

[63] Rothenberg J. L., Sullivan M. A., Church S. H., et al. Behavioral naltrexone therapy: an integrated treatment for opiate dependence *Journal of Substance Abuse Treatment.* 2002;23:351–60.

[64] Hikmayani N. H., Rahardjo S. S., Doewes M.. Correlates of dropout from community-based methadone maintenance treatment program in Indonesia *Value in Health.* 2012;15 (4):A85.

[65] Hojjat S. K., Rezaei M., Hatami S. E., Kohestani M., Norozi Khalili M.. The Effectiveness of Group Family Training About the Principles of Harm Reduction Approach on Marital Satisfaction of Spouses of Patients Under Methadone Maintenance Treatment *Journal of Sex & Marital Therapy.* 2017;43:68–77.

[66] Catalano R. F., Haggerty K. P., Gainey R. R., Hoppe M. J.. Reducing parental risk factors for children's substance misuse: preliminary outcomes with opiate-addicted parents *Substance Use & Misuse.* 1997;32:699–721.

[67] Catalano R. F., Gainey R. R., Fleming C. B., Haggerty K. P., Johnson N. O.. An experimental intervention with families of substance abusers: one-year follow-up of the focus on families project *Addiction.* 1999;94:241–54.

[68] Fals-Stewart W., O'Farrell T. J.. Behavioral family counseling and naltrexone for male opioid-dependent patients *Journal of Consulting & Clinical Psychology.* 2003;71:432–42.

[69] Fals-Stewart W., O'Farrell T. J., Birchler G. R.. Behavioral couples therapy for male methadone maintenance patients: Effects on drug-using behavior and relationship adjustment *Behavior Therapy.* 2001;32:391–411.

[70] Roozen H. G., Kerkhof A. J., Brink W.. Experiences with an outpatient relapse program (community reinforcement approach) combined with naltrexone in the treatment of opioid-dependence: effect on addictive behaviors and the predictive value of psychiatric comorbidity *European Addiction Research.* 2003;9:53–8.

[71] Yandoli Dennis, Eisler Ivan, Robbins Claire, Mulleady Geraldine, Dare Christopher. A comparative study of family therapy in the treatment of opiate users in a London drug clinic *Journal of Family Therapy.* 2002;24:402–422.

[72] Kidorf M.. Mobilizing drug-free support and modifying social network ties using close network supports *Alcoholism: Clinical and Experimental Research.* 2018;42 (Supplement 1):292A.

[73] Ali Mir M, Henke Rachel Mosher, Mutter Ryan, et al. Family member opioid prescriptions and opioid use disorder *Addictive behaviors.* 2019;95:58–63.

[74] Fotiou Anastasios, Kanavou Eleftheria, Richardson Clive, Ploumpidis Dimitrios, Kokkevi Anna. Misuse of prescription opioid analgesics among adolescents in Greece: The importance of peer use and past prescriptions *Drugs: education, prevention and policy.* 2014;21:357–369.

[75] Zanis David A, Coviello Donna. A case study of employment case management with chronically unemployed methadone maintained clients *Journal of psychoactive drugs.* 2001;33:67–73.